G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
Deborah A. Thomas,Susan O'Brien,Stefan Faderl,Guillermo Garcia-Manero,Alessandra Ferrajoli,William G. Wierda,Farhad Ravandi,Srdan Verstovsek,Jeffrey L. Jorgensen,Carlos E. Bueso-Ramos,Michael Andreeff,Sherry Pierce,Rebecca Garris,Michael J. Keating,Jorge E. Cortes,Hagop M. Kantarjian +15 more
TL;DR: The incorporation of rituximab into the hyper-CVAD regimen appears to improve outcome for younger patients with CD20-positive Ph-negative precursor B-lineage ALL.
Journal ArticleDOI
Point-of-care biosensor systems for cancer diagnostics/prognostics
Steven A. Soper,Kathlynn C. Brown,Andrew D. Ellington,Bruno Frazier,Guillermo Garcia-Manero,Vincent Gau,Steven Gutman,Daniel F. Hayes,Brenda Korte,James L. Landers,Dale N. Larson,Frances S. Ligler,Arun Majumdar,Marco Mascini,David D. Nolte,Zeev Rosenzweig,Joseph Wang,David F. Wilson +17 more
TL;DR: This review seeks to provide an overview of the current thinking on molecular profiling for diagnosis and prognosis of cancers and provide insight into the current state-of-the-art in the biosensor field and new strategies that must be considered to bring this important technology into the cancer field.
Journal ArticleDOI
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
Hagop M. Kantarjian,Farhad Ravandi,Susan O'Brien,Jorge E. Cortes,Stefan Faderl,Guillermo Garcia-Manero,Elias J. Jabbour,William G. Wierda,Tapan M. Kadia,Sherry Pierce,Jianqin Shan,Michael J. Keating,Emil J. Freireich +12 more
TL;DR: The prognosis of most patients with acute myeloid leukemia (72%) ≥ 70 years of age with AML is poor with intensive chemotherapy (8-week mortality ≥ 30%; median survival < 6 months).
Journal ArticleDOI
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Naval Daver,Guillermo Garcia-Manero,Sreyashi Basu,Prajwal Boddu,Mansour Alfayez,Jorge E. Cortes,Marina Konopleva,Farhad Ravandi-Kashani,Elias Jabbour,Tapan M. Kadia,Graciela M. Nogueras-Gonzalez,Jing Ning,Naveen Pemmaraju,Courtney D. DiNardo,Michael Andreeff,Sherry Pierce,Tauna Gordon,Steven M. Kornblau,Wilmer Flores,Zainab Al-Hamal,Carlos E. Bueso-Ramos,Jeffrey L. Jorgensen,Keyur P. Patel,Jorge Blando,James P. Allison,Padmanee Sharma,Hagop M. Kantarjian +26 more
TL;DR: Azacitidine in combination with nivolumab therapy produced an encouraging response rate and overall survival in patients with R/R AML, particularly in HMA-naïve and salvage 1 patients.
Journal ArticleDOI
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
William G. Wierda,Susan O'Brien,Xuemei Wang,Stefan Faderl,Alessandra Ferrajoli,Kim Anh Do,Jorge E. Cortes,Deborah A. Thomas,Guillermo Garcia-Manero,Charles Koller,Miloslav Beran,Francis J. Giles,Farhad Ravandi,Susan Lerner,Hagop M. Kantarjian,Michael J. Keating +15 more
TL;DR: A weighted prognostic model, or nomogram, predictive for overall survival was constructed using the following independent characteristics: age, beta-2 microglobulin, absolute lymphocyte count, sex, Rai stage, and number of involved lymph node groups to help patients and clinicians in clinical decision making as well as in clinical research and clinical trial design.